Skip to main content
. 2020 Feb 11;11(6):600–618. doi: 10.18632/oncotarget.27466

Figure 8. Effect of individual mutations and ICB treatment on survival.

Figure 8

Patients with tumors with mutations in TP53, APC, CSMD3, PKHD1, ATM, RNF213, or KMT2D had improved overall survival when treated with ICB. HRs are –Log2 transformed so that a HR of 2 equals 1.0 and a HR of 0.5 equals -1.0. **** p-value < 0.0001; *** p-value < 0.001; ** p-value < 0.01, * p-value < 0.05. Since response to ICB was interrogated in these relationships, only the 490 treated patients were included in this analysis.